CD8A and neoplasm: Tumor immune microenvironment could be classified into four types according to the status of PD-L1 expression and CD8+ TIL abundance (6, 7), while the tumors with tumor microenvironment immune type I (TMIT-I), i.e., with high PD-L1 expression and presence of CD8+ TILs, are more likely to benefit from anti-PD-L1/PD-1 therapies (6).